Investor Presentation H1 2023

42 Investor presentation First six months of 2023 Novo NordiskⓇ Better outcomes and broader reach can be accomplished through continued innovation, supported by digital solutions Digital health solutions Portfolio and pipeline RYBELSUS® semaglutide tablets High dose oral semaglutide Uncontrolled on current OAD Novo Nordisk's product portfolio follows the patient treatment journey OZEMPIC TRESIBA Xultophy RYZODEG Icodec IcoSema semaglutide injection insulin degludec [rDNA origin] injection Ozempic 2.0 mg Needing first injectable Needing first basal insulin Needing more than basal insulin Novo PenⓇ6 / NovoPen Echo® Plus are smart insulin pens and launched in 14 countries 6.2 Abbott Medtronic 600 Roche mySugr glooko Dexcom® Fiasp fast-acting insulin aspart Needing added meal- time insulin control Partnered with global CGM players CGM: Continuous glucose monitoring; Grey boxes in the portfolio and pipeline references phase 2 or phase 3 assets.

View entire presentation